Viralgen

At Viralgen, we’re proud to be known for just one thing: Being the world leader in rAAV-based gene therapy manufacturing. Put simply, we’re all in on AAV; it’s all we do, all day, every day. And our 29-out-of-29 success ratio for IND/IMPD dossiers demonstrates that that focus, experience and commitment deliver clear value to our clients. We grow with them as they move from small feasibility studies to full-on commercial product runs, structuring agreements that deliver them fixed-cost packages, all-inclusive pricing models, and total IP freedom to operate. The bottom line of all that? Gene therapy innovators get to leverage our Pro10 platform and all the experience and data gained with its 1,500+ runs to advance and scale predictably, efficiently and confidently. And patients with rare and ultra-rare genetic diseases get a step closer to the therapies that can make a life-changing and, in some cases, lifesaving, difference.